Literature DB >> 30784041

High-density lipoprotein lipid peroxidation as a molecular signature of the risk for developing cardiovascular disease: Results from MASHAD cohort.

Sara Samadi1,2, Mehrane Mehramiz3, Theodoros Kelesidis4, Majid Ghayour Mobarhan3, Amir Hosein Sahebkar5, Habibollah Esmaily3, Mohsen Moohebati3, Zahra Farjami3, Gordon A Ferns6, Amir Hooshang Mohammadpour7,8, Amir Avan2,3.   

Abstract

High-density lipoprotein (HDL) function rather than level may better predict cardiovascular disease (CVD). However, the contribution of the impaired antioxidant function of HDL that is associated with increased HDL lipid peroxidation (HDLox) to the development of clinical CVD remains unclear. We have investigated the association between serum HDLox with incident CVD outcomes in Mashhad cohort. Three-hundred and thirty individuals who had a median follow-up period of 7 years were recruited as part of the cohort. The primary end point was cardiovascular event, including myocardial infarction, stable angina, unstable angina, or coronary revascularization. In both univariate/multivariate analyses adjusted for traditional CVD risk factors, HDLox was an independent risk factor for CVD (odds ratio, 1.62; 95% confidence interval, 1.41-1.86; p < 0.001). For every increase in HDLox by 0.1 unit, there was an increase in CVD risk by 1.62-fold. In an adjusted analysis, there was a >2.5-fold increase in cardiovascular risk in individuals with HDLox higher than cutoff point of 1.06 compared to those with lower scores, suggesting HDLox > 1.06 is related to the impaired HDL oxidant function and in turn exposed to elevated risk of CVD outcomes (hazard ratio, 2.72; 95% CI, 1.88-3.94). Higher HDLox is a surrogate measure of reduced HDL antioxidant function that positively associated with cardiovascular events in a population-based cohort.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  HDL function; HDLox; antioxidant; high-density lipoprotein; inflammation

Year:  2019        PMID: 30784041      PMCID: PMC6699926          DOI: 10.1002/jcp.28276

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  40 in total

Review 1.  HDL biogenesis and functions: role of HDL quality and quantity in atherosclerosis.

Authors:  Eirini M Tsompanidi; Maria S Brinkmeier; Elisavet H Fotiadou; Smaragda M Giakoumi; Kyriakos E Kypreos
Journal:  Atherosclerosis       Date:  2009-06-06       Impact factor: 5.162

Review 2.  The real role of prediagnostic high-density lipoprotein cholesterol and the cancer risk: a concise review.

Authors:  Juan A Vílchez; Ana Martínez-Ruiz; Natalia Sancho-Rodríguez; Pedro Martínez-Hernández; Jose A Noguera-Velasco
Journal:  Eur J Clin Invest       Date:  2013-11-11       Impact factor: 4.686

3.  The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease.

Authors:  Parin J Patel; Amit V Khera; Kashif Jafri; Robert L Wilensky; Daniel J Rader
Journal:  J Am Coll Cardiol       Date:  2011-11-08       Impact factor: 24.094

Review 4.  The role of dysfunctional HDL in atherosclerosis.

Authors:  Mohamad Navab; Srinivasa T Reddy; Brian J Van Lenten; G M Anantharamaiah; Alan M Fogelman
Journal:  J Lipid Res       Date:  2008-10-27       Impact factor: 5.922

5.  Longitudinal genome-wide association of cardiovascular disease risk factors in the Bogalusa heart study.

Authors:  Erin N Smith; Wei Chen; Mika Kähönen; Johannes Kettunen; Terho Lehtimäki; Leena Peltonen; Olli T Raitakari; Rany M Salem; Nicholas J Schork; Marian Shaw; Sathanur R Srinivasan; Eric J Topol; Jorma S Viikari; Gerald S Berenson; Sarah S Murray
Journal:  PLoS Genet       Date:  2010-09-09       Impact factor: 5.917

6.  Effects of lipid-probe interactions in biochemical fluorometric methods that assess HDL redox activity.

Authors:  Theodoros Kelesidis; Srinivasa T Reddy; Diana Huynh; David Meriwether; Alan M Fogelman; Mohamad Navab; Otto O Yang
Journal:  Lipids Health Dis       Date:  2012-07-06       Impact factor: 4.315

7.  Effects of extended-release niacin with laropiprant in high-risk patients.

Authors:  Martin J Landray; Richard Haynes; Jemma C Hopewell; Sarah Parish; Theingi Aung; Joseph Tomson; Karl Wallendszus; Martin Craig; Lixin Jiang; Rory Collins; Jane Armitage
Journal:  N Engl J Med       Date:  2014-07-17       Impact factor: 91.245

8.  Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s.

Authors:  Theodoros Kelesidis; Thuy Tien T Tran; Todd T Brown; Carlee Moser; Heather J Ribaudo; Michael P Dube; Otto O Yang; Grace A McComsey; James H Stein; Judith S Currier
Journal:  Antivir Ther       Date:  2016-09-23       Impact factor: 1.679

9.  HDL redox activity is increased in HIV-infected men in association with macrophage activation and non-calcified coronary atherosclerotic plaque.

Authors:  Markella V Zanni; Theodoros Kelesidis; Michael L Fitzgerald; Janet Lo; Suhny Abbara; Bryan Wai; Eleni Marmarelis; Nicholas J Hernandez; Otto O Yang; Judith S Currier; Steven K Grinspoon
Journal:  Antivir Ther       Date:  2014-02-17       Impact factor: 1.679

10.  Impact of Lifestyle Intervention on HDL-Induced eNOS Activation and Cholesterol Efflux Capacity in Obese Adolescent.

Authors:  Jenny Wesnigk; Luc Bruyndonckx; Vicky Y Hoymans; Ann De Guchtenaere; Tina Fischer; Gerhard Schuler; Christiaan J Vrints; Volker Adams
Journal:  Cardiol Res Pract       Date:  2016-11-14       Impact factor: 1.866

View more
  2 in total

1.  Race and sex differences in HDL peroxide content among American adults with and without type 2 diabetes.

Authors:  Shelby M Flaherty; Elizabeth K Wood; Carol D Ryff; Gayle D Love; Theodoros Kelesidis; Loni Berkowitz; Guadalupe Echeverría; Katherine Rivera; Attilio Rigotti; Christopher L Coe
Journal:  Lipids Health Dis       Date:  2022-02-06       Impact factor: 3.876

2.  Identification of N-benzothiazolyl-2-benzenesulfonamides as novel ABCA1 expression upregulators.

Authors:  Hongtao Liu; Xinhai Jiang; Xinfeng Gao; Wenhua Tian; Chen Xu; Ruizhi Wang; Yanni Xu; Liping Wei; Feng Cao; Wenyan Li
Journal:  RSC Med Chem       Date:  2020-03-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.